Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial

Next Previous
Trial Profile

A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Dinutuximab beta (Primary) ; Temozolomide (Primary) ; Cyclophosphamide; Irinotecan; Topotecan
  • Indications Neuroblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms BEACON; BEACON-Immuno; BEACON-Neuroblastoma Trial; ITCC-SIOPEN BEACON

Most Recent Events

  • 22 May 2024 According to an ORPHELIA Pharma, overall, anonymised data from the BEACON trial are being used to support the registration dossier of KIZFIZO, according to a data sharing agreement drawn up by University of Birmingham Enterprise. The data from this trial will support registration of for a new liquid formulation temozolomide.
  • 13 May 2024 Planned End Date changed from 1 Dec 2026 to 1 Feb 2026.
  • 08 Jan 2024 Primary endpoint has not been met. (Best response (Complete Response or Partial Response) while on trial treatment, within 18 or 24 weeks depending on the arm of the trial participant is randomised to), as per Results published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top